In most cases, it is feasible and only a minor inconvenience to wait a few days for a blood draw to obtain a 4Kscore. However, in a tertiary care setting or other practices with a large referral area, it can be a significant burden for patients from far away to wait a few days and return for a blood draw. As there are no studies in the literature examining the effect of DRE prior to 4Kscore blood draw, we investigated whether performing a DRE prior to a blood draw results in statistically and/or clinically significant changes in the 4Kscore. procedure within the prior 6 months from this study but they were eligible to participate in the other screening and educational activities of the event.
| MATERIALS AND METHODS

| Study population
| Data collection
Patients filled out a clinical history questionnaire including demographic and clinical information, then underwent a blood draw prior to DRE and screening discussion with one of seven physicians volunteering at the event. Fifteen to 45 min after the DRE, the patients underwent a second blood draw. Time interval from DRE to this second blood draw was recorded.
| Sample preparation
Venous blood samples were collected in a K2EDTA tube (Lavender top) with approximately 7.5 mL of blood (at least 5 mL of blood). To ensure good mixing with the EDTA, the tube of blood was inverted eight times shortly after sample collection. These quantities of blood ensure that enough plasma can be obtained. The single determination of the four kallikrein markers requires approximately 1 mL of plasma, and the Laboratory requires 2 mL of plasma to allow re-run of the sample, as needed.
Blood samples were stored at 2 to 8°C and centrifuged within 60 h of collection at 1000g for 10 min. Plasma samples were sent to OPKO Lab for analysis.
| Hypothesis
Our hypothesis was that there would not be a difference between pre-and post-DRE 4Kscore values.
| Data analysis
Pre-and post-DRE 4Kscore values were compared using
Wilcoxon signed-rank test and Passing-Bablok regression analysis.
Multivariate regression analysis was also performed to examine potential association between patient clinical factors (age, DRE 
| RESULTS
A total of 162 PCAW patients met inclusion criteria and consented to participate in our study. Study population baseline characteristics are reported in Table 1 . A small but statistically significant increase (P ≤ 0.05) in the medians and interquartile ranges (IQR) were seen in levels of three kallikreins after DRE − tPSA (median = +0.027 ng/mL, IQR = −0.03-0.10), fPSA (median = +0.024, IQR = −0.001-0.066), and iPSA (median = +0.012, IQR = −0.003-0.033) as reported in the Table 2 . Variations in the levels of hk2 were not significantly different (median change = 0 ng/mL, IQR = −0.002-0.001). The net effect of these changes was a median absolute decrease in 4Kscore of 0.43% (IQR = −0.91% to −0.04%). Multivariate logistic regression analysis demonstrated that positive DRE and increasing age were independently associated with increase in post-DRE fPSA (P = 0.025 and P = 0.017, respectively) and decrease in post-DRE 4Kscore (P = 0.017 and P = 0.006, respectively).
Other factors examined in the multivariate regression which did not demonstrate any independent effect on the degree of change in 4Kscore included patient race (Caucasian versus African American), prior negative biopsy history, and time to second blood draw.
Using a 4Kscore of 7.5% as a theoretical trigger for prostate biopsy, we found that 10 patients (6.2% of participants) would be reclassified based on change in 4Kscore; 9 of these patients had a 4Kscore greater than 7.5% prior to DRE and 4Kscore less than 7.5%
after DRE while one patient had an initial 4Kscore less than 7.5%
prior to DRE and greater than 7.5% after DRE. Thus, a statistically significant proportion of men at risk for high grade prostate cancer with pre-DRE 4Kscore ≥ 7.5% were downgraded by post-DRE 4Kscore <7.5% compared to those upgraded (McNemar's test P ≤ 0.022). These results are reported in Table 3 . All ten of these patients had an initial 4Kscore between 5% and 10% and post-DRE 4Kscores remained between 5% and 10%. The absolute change in results from pre-to post-DRE 4Kscore among patients with initial 4Kscore between 5% and 10% ranged from −3.7% to +1.2%.
| DISCUSSION
Overall changes in kallikrein levels measured in our study were small, with median change less than 0.03 ng/mL for all four measured. The majority of change was seen in free PSA levels. These changes resulted in a median decrease in the 4Kscore of less than 0.5%. With a median pre-DRE 4Kscore of 4.8%, this represents a small change. Our data demonstrate that while a DRE prior to blood draw appears to result in a statistically significant change in 4Kscore, this small change is clinically insignificant in the overwhelming majority of cases (about 94%). As a result, a significantly higher proportion of men will be downgraded from high-risk to low-risk for high-grade prostate cancer than those upgraded. Due to lack of biopsy information for this cohort (limitations discussed further below), we are unable to assess the clinical impact.
However, the overall range of change in 4Kscore was −9.5% to +1.5%, which is enough to potentially impact clinical decision-making, particularly in patients with 4Kscore values near the biopsy threshold of 7.5%.
Our study does have several limitations. First, the study population is at risk of selection bias, given that these are men who voluntarily chose to seek annual prostate cancer screening and education at our PCAW event. Second, DRE technique could potentially have some effect on the degree of change in serum kallikreins. Having multiple providers performing DREs should hopefully have limited this effect to some degree. We did retrospectively look at the providers who performed DREs on patients with absolute change in 4Kscore greater than 1.5%, and all providers were represented in this group in similar numbers. Third, although we did this study in a prospective fashion, one could argue that including controls undergoing two 4Kscore blood draws without an intervening DRE could help by providing comparison to the effect of variation between sequential blood draws alone. Finally, the nature of this study at an informational event certainly introduces a limitation due to the fact that while patients undergoing screening receive advice to seek follow up to discuss abnormal test results, we do not have access to information about how many patients actually proceeded to biopsy nor to pathology results from those who subsequently did so, as patients who did seek further evaluation likely did so across multiple locations and providers, many outside of our health system. In an ideal study all patients undergoing blood testing would also have undergone prostate biopsy, but this would have exposed many patients to potential unnecessary harm and thus was ethically not feasible.
| CONCLUSIONS
We conclude that while a DRE does appear to have a minor effect on 4Kscore results, the impact of the change is small and is unlikely to affect clinical decision making in the overwhelming majority of cases.
Ideally, it is preferable for a blood draw to be performed prior to DRE, however a DRE should not necessarily preclude a patient from undergoing a subsequent 4Kscore blood draw at the same visit. If the 4Kscore result is less than 5% or greater than 10%, we feel the clinician can be confident that the result is reliable even after a recent DRE. However, physicians and their patients with 4Kscore
results between 5% and 10% should consider the possibility that DRE caused the result to change relative to the 7.5% threshold and consider if such a change would alter management decisions. It is important to also keep in mind that while a value of 7.5% is often used as a trigger for prostate biopsy, this is not an absolute cutoff; rather, the 4Kscore is meant to be considered in conjunction with other patient information to aid the physician and patient in making management decisions. 
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